Tectonic Therapeutic
CompanyUnited States
Tectonic Therapeutic develops 2 assets, the furthest in phase 2 (TX000045 in heart failure with preserved ejection fraction). Mostly protein or enzyme; based in the United States.
- 2
- Assets
- Furthest stage
- Phase 2
- Raised
- $131M
- 1
- Trial
- 0
- Signals
Pipeline
2Modulates GPCR signaling to treat pulmonary hypertension associated with heart failure with preserved ejection fraction.
Phase 2, Protein or enzyme, heart failure with preserved ejection fraction, pulmonary hypertension
Fc-relaxin fusion protein that activates the relaxin receptor RXFP1 to promote vasodilation.
Stage not known, Protein or enzyme
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- Funding rounds and grants1
- Deals4
- Similar companies6